Immunology/Inflammation
Immunology/Inflammation(免疫及炎症)
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
- 5-Lipoxygenase(11)
- Papain(1)
- PGDS(1)
- PGE synthase(24)
- SIKs(12)
- IκB/IKK(67)
- AP-1(6)
- KEAP1-Nrf2(65)
- NOD1(1)
- TLR(140)
- NF-κB(241)
- Interleukin Related(171)
- 15-lipoxygenase(2)
- Others(63)
- Aryl Hydrocarbon Receptor(36)
- CD73(14)
- Complement System(58)
- Galectin(12)
- IFNAR(25)
- NO Synthase(77)
- NOD-like Receptor (NLR)(51)
- STING(110)
- Reactive Oxygen Species(465)
- Apoptosis(802)
- FKBP(20)
- eNOS(5)
- iNOS(29)
- nNOS(20)
- Glutathione(57)
- Adaptive Immunity(222)
- Allergy(130)
- Arthritis(34)
- Autoimmunity(190)
- Gastric Disease(101)
- Immunosuppressants(39)
- Immunotherapeutics(5)
- Innate Immunity(593)
- Pulmonary Diseases(119)
- Reactive Nitrogen Species(55)
- Reactive Sulfur Species(28)
- Specialized Pro-Resolving Mediators(50)
- Cyclic GMP-AMP Synthase(2)
- BCL6(3)
- CD20(3)
- CD22
- CD28(1)
- FAP(7)
- PSMA(7)
- Nuclear Factor of activated T Cells (NFAT)(1)
- Glycoprotein VI(1)
- Tim3(2)
- Hapten(1)
- Nectin-4(2)
Immunology/Inflammation 相关产品(4245)
- GC68346UliledlimabCAS: 2378407-27-1
Uliledlimab 是一种有效的抗 CD73 人源单克隆抗体。Uliledlimab 抑制胞外单磷酸腺苷 (AMP) 向腺苷的转化。Uliledlimab 可用于癌症的研究。
- GC68379L-Arginine-13C6,15N4 hydrochlorideCAS: 202468-25-5纯度: >99.00%
L-Arginine-13C6,15N4 ((S)-(+)-Arginine-13C6,15N4) hydrochloride 是带有 13C 标记和 15N 标记的 L-Arginine hydrochloride。L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) 为合成一氧化氮的氮供体,是血管扩张剂。
- GC684522,4,6-TriiodophenolCAS: 609-23-4纯度: >98.00%
2,4,6-Triiodophenol 是一种具有口服活性的、强效的 leukotriene B4 (LTB4) 合成抑制剂。2,4,6-Triiodophenol 可诱导小鼠囊胚凋亡。
- GC685625-Aminolevulinic acid-13C-1 hydrochlorideCAS: 129720-94-1纯度: >98.00%
5-Aminolevulinic acid-13C-1 (5-ALA-13C-1) hydrochloride 是 13C 标记的 5-Aminolevulinic acid hydrochloride。5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) 是体内血红素生物合成的中间体,为四吡咯的前体。
- GC685766'-SialyllactoseCAS: 35890-39-2
6'-Sialyllactose 是一种唾液酸化的人乳低聚糖,可以促进双歧杆菌的增殖并塑造肠道菌群。6'-Sialyllactose 还抑制 toll-like receptor 4 信号转导并防止坏死性小肠结肠炎的发展。
- GC68595AbrezekimabCAS: 2043952-59-4纯度: >95.00%
Abrezekimab (VR 942) 含有 CDP7766,这是一种人源化、高亲和力、中和性、抗人 IL-13 抗体片段,可与 IL-13 结合。Abrezekimab 阻止与 IL-13Rα1 亚基的结合。Abrezekimab 可用于哮喘的研究。
- GC68631AhR agonist 2纯度: >99.50%
AhR agonist 2 (Compound 12a) 是一种有效的芳烃受体 (AhR) 激动剂,EC50 为 0.03 nM。AhR agonist 2 诱导 AhR 的快速核富集,触发下游基因的转录并促进皮肤屏障修复。AhR agonist 2 具有研究银屑病的潜力。
- GC68632AK-778-XXMUCAS: 1227045-76-2纯度: >98.50%
AK-778-XXMU是DNA结合2 (ID2) 拮抗剂的有效抑制剂,KD为129 nM。AK-778-XXMU 能抑制胶质瘤细胞株的迁移和侵袭,诱导细胞凋亡 (apoptosis),更重要的是能减缓肿瘤生长。
- GC68649AmaroswerinCAS: 21233-18-1
Amaroswerin 是一种从獐牙菜中提取的具有生物活性的硫环烯醚萜苷。Amaroswerin 具有抗炎、抗糖尿病、抗病毒、抗胆碱能和免疫调节活性。在 RAW264.7 细胞中,Amaroswerin 抑制 NO 释放,IC50 值为 5.42 μg/mL。
- GC68702AstegolimabCAS: 2173054-79-8纯度: >95.00%
Astegolimab (MSTT 1041A; RG 6149) 是一种人 IgG2 单克隆抗体,可通过靶向 IL-33 受体 ST2 来阻断 IL-33 信号传导。Astegolimab 具有用于慢性阻塞性肺疾病 (COPD) 研究的潜力。
- GC68709AvizakimabCAS: 2229685-51-0纯度: >95.00%
Avizakimab (BOS161721) 是一种人源化 IgG1 单克隆抗体,靶向白介素-21 (IL-21)。
- GC68753BermekimabCAS: 1401965-15-8纯度: >95.00%
Bermekimab (MABp1) 是一种靶向白介素-1alpa (IL-1α) 的人单克隆抗体。Bermekimab 可预防肿瘤相关炎症。
- GC68757BH3 hydrochloride纯度: >98.00%
BH3 hydrochloride 是能透过血脑屏障的多肽,通过直接激活促凋亡 Bax/Bak 或通过中和抗凋亡 Bcl-2 蛋白 (Bcl-2、Bcl-XL、Bcl-w、mcl1和A-1)来诱导细胞凋亡,通过与BH3 结构域结合。
- GC68769Biotin-COG1410 TFA纯度: >99.00%
Biotin-COG1410 TFA 是生物素化的 COG1410 。COG1410 是一种载脂蛋白 E 的衍生肽和凋亡 (apoptosis) 抑制剂。COG1410 在小鼠颅脑损伤 (TBI) 模型中发挥神经保护和抗炎作用。COG1410 可用于神经系统疾病的研究。
- GC68774Bleomycin A5CAS: 11116-32-8
Bleomycin A5 (Pingyangmycin) 是糖肽类抗生素,具有口服活性。Bleomycin A5 具有抗肿瘤剂、细胞凋亡诱导剂和细菌代谢物的作用。
- GC68807BriakinumabCAS: 339308-60-0纯度: >95.00%
Briakinumab (ABT-874) 是一种全人抗 IL-12/23p40 单克隆抗体。Briakinumab 靶向并中和 IL-12 和 IL-23。Briakinumab 可用于类风湿性关节炎、炎症性肠病和多发性硬化症的研究。
- GC68854Cergutuzumab amunaleukinCAS: 1509916-03-3纯度: >98.00%
Cergutuzumab amunaleukin (CEA-IL2v) 是一种基于癌胚抗原 (CEA) 靶向 IL-2 变体的免疫细胞因子。Cergutuzumab amunaleukin 具有免疫刺激和抗肿瘤活性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC68346 | Uliledlimab | 2378407-27-1 | - | |
Uliledlimab 是一种有效的抗 CD73 人源单克隆抗体。Uliledlimab 抑制胞外单磷酸腺苷 (AMP) 向腺苷的转化。Uliledlimab 可用于癌症的研究。 | ||||
| GC68379 | L-Arginine-13C6,15N4 hydrochloride | 202468-25-5 | >99.00% | |
L-Arginine-13C6,15N4 ((S)-(+)-Arginine-13C6,15N4) hydrochloride 是带有 13C 标记和 15N 标记的 L-Arginine hydrochloride。L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) 为合成一氧化氮的氮供体,是血管扩张剂。 | ||||
| GC68386 | CD73-IN-5 | 2412019-99-7 | - | |
CD73-IN-5 是一种有效且选择性的非核苷酸小分子 CD73 抑制剂(IC50 = 19 nM)。 | ||||
| GC68432 | DB-3-291 | - | - | |
DB-3-291 是一种有效和选择性的 CSK 降解剂,Kd 值为 1 nM。 | ||||
| GC68452 | 2,4,6-Triiodophenol | 609-23-4 | >98.00% | |
2,4,6-Triiodophenol 是一种具有口服活性的、强效的 leukotriene B4 (LTB4) 合成抑制剂。2,4,6-Triiodophenol 可诱导小鼠囊胚凋亡。 | ||||
| GC68461 | TrxR-IN-5 | - | - | |
TrxR-IN-5 (化合物 4f) 是一种有效的 TrxR 硫氧还蛋白还原酶抑制剂,其 IC50 值为 0.16 μM。TrxR-IN-5 增加 ROS 水平,从而产生有效的抗增殖作用。TrxR-IN-5 具有显著的抗肿瘤和抗转移作用。 | ||||
| GC68562 | 5-Aminolevulinic acid-13C-1 hydrochloride | 129720-94-1 | >98.00% | |
5-Aminolevulinic acid-13C-1 (5-ALA-13C-1) hydrochloride 是 13C 标记的 5-Aminolevulinic acid hydrochloride。5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) 是体内血红素生物合成的中间体,为四吡咯的前体。 | ||||
| GC68576 | 6'-Sialyllactose | 35890-39-2 | - | |
6'-Sialyllactose 是一种唾液酸化的人乳低聚糖,可以促进双歧杆菌的增殖并塑造肠道菌群。6'-Sialyllactose 还抑制 toll-like receptor 4 信号转导并防止坏死性小肠结肠炎的发展。 | ||||
| GC68595 | Abrezekimab | 2043952-59-4 | >95.00% | |
Abrezekimab (VR 942) 含有 CDP7766,这是一种人源化、高亲和力、中和性、抗人 IL-13 抗体片段,可与 IL-13 结合。Abrezekimab 阻止与 IL-13Rα1 亚基的结合。Abrezekimab 可用于哮喘的研究。 | ||||
| GC68631 | AhR agonist 2 | - | >99.50% | |
AhR agonist 2 (Compound 12a) 是一种有效的芳烃受体 (AhR) 激动剂,EC50 为 0.03 nM。AhR agonist 2 诱导 AhR 的快速核富集,触发下游基因的转录并促进皮肤屏障修复。AhR agonist 2 具有研究银屑病的潜力。 | ||||
| GC68632 | AK-778-XXMU | 1227045-76-2 | >98.50% | |
AK-778-XXMU是DNA结合2 (ID2) 拮抗剂的有效抑制剂,KD为129 nM。AK-778-XXMU 能抑制胶质瘤细胞株的迁移和侵袭,诱导细胞凋亡 (apoptosis),更重要的是能减缓肿瘤生长。 | ||||
| GC68649 | Amaroswerin | 21233-18-1 | - | |
Amaroswerin 是一种从獐牙菜中提取的具有生物活性的硫环烯醚萜苷。Amaroswerin 具有抗炎、抗糖尿病、抗病毒、抗胆碱能和免疫调节活性。在 RAW264.7 细胞中,Amaroswerin 抑制 NO 释放,IC50 值为 5.42 μg/mL。 | ||||
| GC68700 | ASR-488 | 2690312-65-1 | >99.00% | |
ASR-488 可激活 mRNA 结合蛋白 CPEB1,诱导细胞凋亡 (apoptosis) 并抑制膀胱癌的生长。 | ||||
| GC68702 | Astegolimab | 2173054-79-8 | >95.00% | |
Astegolimab (MSTT 1041A; RG 6149) 是一种人 IgG2 单克隆抗体,可通过靶向 IL-33 受体 ST2 来阻断 IL-33 信号传导。Astegolimab 具有用于慢性阻塞性肺疾病 (COPD) 研究的潜力。 | ||||
| GC68709 | Avizakimab | 2229685-51-0 | >95.00% | |
Avizakimab (BOS161721) 是一种人源化 IgG1 单克隆抗体,靶向白介素-21 (IL-21)。 | ||||
| GC68743 | BBIQ | 1229024-57-0 | - | |
BBIQ 是一种咪唑喹啉化合物,也是一种有效且选择性的 toll 样受体 7 (TLR7) 激动剂,对人 TLR7 的 EC50 为 59.1 nM。BBIQ 还是一种功能强大的疫苗佐剂,可增强机体的先天免疫应答。 | ||||
| GC68744 | BC-?1258 | 1507370-40-2 | - | |
BC-1258 是一种 F-box/LRR-重复蛋白 2 (FBXL2) 激活剂,可以稳定和上调 FBXL2 水平。BC-1258 诱导致瘤细胞凋亡,并显着抑制小鼠的肿瘤形成。 | ||||
| GC68753 | Bermekimab | 1401965-15-8 | >95.00% | |
Bermekimab (MABp1) 是一种靶向白介素-1alpa (IL-1α) 的人单克隆抗体。Bermekimab 可预防肿瘤相关炎症。 | ||||
| GC68757 | BH3 hydrochloride | - | >98.00% | |
BH3 hydrochloride 是能透过血脑屏障的多肽,通过直接激活促凋亡 Bax/Bak 或通过中和抗凋亡 Bcl-2 蛋白 (Bcl-2、Bcl-XL、Bcl-w、mcl1和A-1)来诱导细胞凋亡,通过与BH3 结构域结合。 | ||||
| GC68769 | Biotin-COG1410 TFA | - | >99.00% | |
Biotin-COG1410 TFA 是生物素化的 COG1410 。COG1410 是一种载脂蛋白 E 的衍生肽和凋亡 (apoptosis) 抑制剂。COG1410 在小鼠颅脑损伤 (TBI) 模型中发挥神经保护和抗炎作用。COG1410 可用于神经系统疾病的研究。 | ||||
| GC68774 | Bleomycin A5 | 11116-32-8 | - | |
Bleomycin A5 (Pingyangmycin) 是糖肽类抗生素,具有口服活性。Bleomycin A5 具有抗肿瘤剂、细胞凋亡诱导剂和细菌代谢物的作用。 | ||||
| GC68807 | Briakinumab | 339308-60-0 | >95.00% | |
Briakinumab (ABT-874) 是一种全人抗 IL-12/23p40 单克隆抗体。Briakinumab 靶向并中和 IL-12 和 IL-23。Briakinumab 可用于类风湿性关节炎、炎症性肠病和多发性硬化症的研究。 | ||||
| GC68826 | Cantrixil | 2135511-22-5 | - | |
Cantrixil (TRX-E-002-1) 是 TRX-E-002 的活性对映异构体,是第二代超级苯并吡喃 (SBP) 化合物。Cantrixil 增加磷酸化 c-Jun 水平,导致卵巢癌细胞中半胱天冬酶介导的细胞凋亡。Cantrixil 对广泛的癌症表型具有有效的抗癌活性。 | ||||
| GC68854 | Cergutuzumab amunaleukin | 1509916-03-3 | >98.00% | |
Cergutuzumab amunaleukin (CEA-IL2v) 是一种基于癌胚抗原 (CEA) 靶向 IL-2 变体的免疫细胞因子。Cergutuzumab amunaleukin 具有免疫刺激和抗肿瘤活性。 | ||||
